biomea fusion
Sheldon Wang is a highly experienced scientist currently serving as a Senior Scientist II at Biomea Fusion since May 2021. Prior to this role, Sheldon held various positions at R2M Pharma, Inc. as a Scientist and Sr. Associate Scientist from July 2017 to April 2021. Additional experience includes roles as Sr. Associate Scientist at Amgen from March 2006 to December 2014, and Sr. Assistant Chemist at Eli Lilly from March 2000 to March 2006. Sheldon began a career in the industry at Abbott Laboratories as a Chemist from September 1994 to March 2000. Educational qualifications include a Master of Science in Organic Chemistry from The University of Memphis and two degrees from Beijing Normal University, including a Master of Science in Inorganic Chemistry and a Bachelor of Science in Chemistry.
biomea fusion
Biomea Fusion, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was formed in 2017 by a small group of biotech executives that came together with the common goal of achieving better therapies for patients.